73 related articles for article (PubMed ID: 28561692)
1. Health Disparities and the Global Landscape of Lymphoma Care Today.
Phillips AA; Smith DA
Am Soc Clin Oncol Educ Book; 2017; 37():526-534. PubMed ID: 28561692
[TBL] [Abstract][Full Text] [Related]
2. Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study.
Cerhan JR; Engels EA; Cozen W; Davis S; Severson RK; Morton LM; Gridley G; Hartge P; Linet M
Int J Cancer; 2008 Aug; 123(4):888-94. PubMed ID: 18506687
[TBL] [Abstract][Full Text] [Related]
3. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies.
Kane EV; Bernstein L; Bracci PM; Cerhan JR; Costas L; Dal Maso L; Holly EA; La Vecchia C; Matsuo K; Sanjose S; Spinelli JJ; Wang SS; Zhang Y; Zheng T; Roman E; Kricker A;
Ann Oncol; 2013 Feb; 24(2):433-441. PubMed ID: 22967995
[TBL] [Abstract][Full Text] [Related]
4. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy.
Chihara D; Nastoupil LJ; Williams JN; Lee P; Koff JL; Flowers CR
Expert Rev Anticancer Ther; 2015 May; 15(5):531-44. PubMed ID: 25864967
[TBL] [Abstract][Full Text] [Related]
5. Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.
El-Mallawany NK; Alexander S; Fluchel M; Hayashi RJ; Lowe EJ; Giulino-Roth L; Wistinghausen B; Hermiston M; Allen CE;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30565. PubMed ID: 37449925
[TBL] [Abstract][Full Text] [Related]
6. Knowledge of Clinical Trial Availability and Reasons for Nonparticipation Among Adolescent and Young Adult Cancer Patients: A Population-based Study.
Shnorhavorian M; Doody DR; Chen VW; Hamilton AS; Kato I; Cress RD; West M; Wu XC; Keegan THM; Harlan LC; Schwartz SM;
Am J Clin Oncol; 2018 Jun; 41(6):581-587. PubMed ID: 27635619
[TBL] [Abstract][Full Text] [Related]
7. The quest for a cure in follicular lymphoma.
Tonino SH; Kersten MJ
Blood; 2024 Feb; 143(6):475-476. PubMed ID: 38329775
[No Abstract] [Full Text] [Related]
8. Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study.
Schulpen M; Beishuizen A; Chamuleau MED; Dinmohamed AG; Meyer-Wentrup FAG; Vormoor HJ; Van der Wagen LE; Minnema MC; Loeffen JLC; Karim-Kos HE
Haematologica; 2024 Mar; 109(3):936-941. PubMed ID: 37646666
[No Abstract] [Full Text] [Related]
9. Trends and Disparities in Cardiovascular Death in Non-Hodgkin Lymphoma.
Tan MC; Yeo YH; Ibrahim R; Tan MX; Lee JZ; Deshmukh AJ; Guha A
Am J Cardiol; 2024 Jan; 210():276-278. PubMed ID: 37945468
[No Abstract] [Full Text] [Related]
10. Age and Sex in Non-Hodgkin Lymphoma Therapy: It's Not All Created Equal, or Is It?
Pfreundschuh M
Am Soc Clin Oncol Educ Book; 2017; 37():505-511. PubMed ID: 28561693
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab: what is there to learn from clinical trials?
Cartron G; Watier H
Blood; 2017 Aug; 130(5):581-589. PubMed ID: 28584136
[TBL] [Abstract][Full Text] [Related]
12. Pros and cons of rituximab maintenance in follicular lymphoma.
Zhang L; Ghielmini M; Cheson BD; Ujjani C
Cancer Treat Rev; 2017 Jul; 58():34-40. PubMed ID: 28628883
[TBL] [Abstract][Full Text] [Related]
13. Racial and ethnic disparities in hematologic malignancies.
Kirtane K; Lee SJ
Blood; 2017 Oct; 130(15):1699-1705. PubMed ID: 28724539
[TBL] [Abstract][Full Text] [Related]
14. Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region.
Ayers AA; Lyu L; Dance K; Ward KC; Flowers CR; Koff JL; McCullough LE
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):699-708.e5. PubMed ID: 31494062
[TBL] [Abstract][Full Text] [Related]
15. Global patterns and trends in the incidence of non-Hodgkin lymphoma.
Miranda-Filho A; Piñeros M; Znaor A; Marcos-Gragera R; Steliarova-Foucher E; Bray F
Cancer Causes Control; 2019 May; 30(5):489-499. PubMed ID: 30895415
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.
Rho H; Jeong IJ; Prica A
Curr Oncol; 2023 Dec; 30(12):10488-10500. PubMed ID: 38132398
[TBL] [Abstract][Full Text] [Related]
17. Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma.
Devi K; Soomar SM; Shaikh MU; Ali N
Ann Med Surg (Lond); 2023 Sep; 85(9):4256-4261. PubMed ID: 37663724
[TBL] [Abstract][Full Text] [Related]
18. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Arshad S; Fang X; Ahn KW; Kaur M; Scordo M; Sauter CS; Furqan F; Awan FT; Hamadani M
Bone Marrow Transplant; 2023 Nov; 58(11):1203-1208. PubMed ID: 37563283
[TBL] [Abstract][Full Text] [Related]
19. Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma.
Gupta V; Singh V; Bajwa R; Meghal T; Sen S; Greenberg D; Anne M; Levitt MJ
J Hematol; 2022 Apr; 11(2):45-54. PubMed ID: 35573751
[TBL] [Abstract][Full Text] [Related]
20. Challenges in Access to New Therapeutic Agents: Marginalized Patients With Cancer in Pakistan and the Need for New Guidelines.
Aziz Z; Naseer H; Altaf A
JCO Glob Oncol; 2022 Feb; 8():e2100132. PubMed ID: 35175831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
